Essai clinique 2026-525170-19-00 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Recherche en oncologie
14/09/2026
Essai clinique 2026-525170-19-00 (phase II) est «autorisé» sur CTIS (EU Clinical Trials Information System).
Pathologie: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · Interventions enregistrées: Entyvio 300 mg powder for concentrate for solution for infusion, BNT327 20 mg ml, PACLITAXEL, BNT327 50 mg ml, CARBOPLATIN, INFLIXIMAB, CISPLATIN, PEMETREXED, Anti-CCR8 NF mAb · Dates enregistrées (source): 2026-09-07, 2026-09-10.
Source: https://euclinicaltrials.eu/ctis-public/view/2026-525170-19-00